USPTO Patent Grant: AAV vectors for Schwann cell diseases

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted patent US12582725B2 for AAV vectors with a myelin protein zero promoter, designed for treating Schwann cell-associated diseases like Charcot-Marie-Tooth disease. The patent was assigned to The Cyprus Foundation for Muscular Dystrophy Research.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582725B2, titled "AAV vectors with myelin protein zero promoter and uses thereof for treating SCHWANN cell-associated diseases like CHARCOT-MARIE-TOOTH disease." The patent, assigned to The Cyprus Foundation for Muscular Dystrophy Research, covers viral vectors, specifically adeno-associated vectors (AAV) with a Schwann cell-specific promoter, for delivering polynucleotides to Schwann cells to treat and prevent diseases such as Charcot-Marie-Tooth disease and other demyelinating neuropathies.

This patent grant is a routine event for the USPTO and does not impose new regulatory obligations on regulated entities. However, it signifies intellectual property protection for specific therapeutic technologies in the biotechnology and pharmaceutical sectors. Companies operating in this space should be aware of this granted patent when developing or commercializing related AAV vector technologies for neurological disorders.

Source document (simplified)

← USPTO Patent Grants

AAV vectors with myelin protein zero promoter and uses thereof for treating SCHWANN cell-associated diseases like CHARCOT-MARIE-TOOTH disease

Grant US12582725B2 Kind: B2 Mar 24, 2026

Assignee

THE CYPRUS FOUNDATION FOR MUSCULAR DYSTROPHY RESEARCH

Inventors

Kleopas Kleopa, Alexia Kagiava, Natasa Schiza, Irene Sargiannidou

Abstract

The present invention provides viral vectors for use in the treatment and prevention of diseases associated with Schwann cells by delivering polynucleotides specifically to Schwann cells and achieving Schwann cell specific expression. The present invention has particular application in treatment and prevention of Charcot-Marie-Tooth disease and other demyelinating neuropathies. The preferred vectors are adeno-associated vectors (AAV) having a Schwann cell-specific promoter from the Myelin Protein Zero (Mpz, P0) or a minimal Mpz promoter.